Luminal typing refers to the typing of a patient’s breast cancer cells that are estrogen receptor positive and progesterone and HER2 receptor negative, and stage II refers to the clinical stage of the patient’s tumor.
Breast cancer cells can be pathologically molecularly typed based on estrogen receptor, progesterone receptor, HER-2 receptor, and KI-67 index on the surface of the cancer cells.
Luminal B refers to patients with high expression of estrogen receptor, low or no expression of progesterone receptor, no expression of HER-2 receptor, and high expression of KI-67 index on the surface of cancer cells. It means that the patient’s adjuvant treatment regimen can add endocrine therapy drugs.
Stage II refers to the clinical staging of the tumor by the clinician based on the size of the patient’s tumor, peripheral lymph node metastasis, and the presence of distant metastases. Stage II refers to patients whose tumors are mainly smaller than 5 cm and have not yet developed distant metastases, but there are local or regional lymph node metastases.